HOME >> BIOLOGY >> NEWS
Genetically Engineered Mice Show Characteristic Signs Of Alzheimer's, Could Be Ideal Tool For Testing New Therapies

out treatments to combat these detrimental effects."

The work was conducted by investigators at the Gladstone Institute of Neurological Disease, a major new research enterprise based at the San Francisco General Hospital campus of UCSF. The results are published in the Sept. 1 issue of Proceedings of the National Academy of Sciences U.S.A.

In one experiment, mice had to learn the location of a hidden target in a maze that tests their ability to remember and process spatial information. Similar skills are strongly affected in Alzheimer's patients, who often get lost because they have trouble finding their way home.

ApoE3 mice learned how to find the hidden target with relative ease, whereas their apoE4 counterparts had difficulty with the exercise, and some never found the target at all even after repeated tries. Consistent with the age dependence of Alzheimer's disease, only older apoE4 mice showed deficits in learning and memory, whereas young apoE4 mice were not impaired.

In another experiment, mice were placed in an open field inside a cage, and their movements were monitored with motion sensors. Older apoE4 mice showed much less exploratory curiosity in this test than age-matched apoE3 mice. The investigators speculate that these findings might also relate to Alzheimer's patients, who often lose interest in their environment and abandon activities that once engaged them.

In both experiments, the researchers noticed a distinct difference in behavior between female and male mice, with the females experiencing a higher level of impairment. These results are consistent with clinical studies by other investigators which suggest that apoE4 increases Alzheimer's risk and decreases responsiveness to treatments more strongly in women than in men.

The researchers already have begun to manipulate the levels of apoE4 in the brains of these mice to see what impact these changes might have on their behavior. Mucke said
'"/>

Contact: Corinna Kaarlela
corinna@itsa.ucsf.edu
(415) 476-3804
University of California - San Francisco
31-Aug-1998


Page: 1 2 3

Related biology news :

1. Genetically modified bacterium as remedy for intestinal diseases
2. Genetically-engineered marathon mouse keeps on running
3. Purdue scientists: Genetically modified fish could damage ecology
4. Genetically modified E. coli produce plant product used in foods and cosmetics, Science study says
5. Genetically modified crops not necessarily a threat to the environment
6. Genetically modified mice provide information on treatments for cocaine dependence
7. Genetically engineered mice offer hope for isolating beta cells and treatment of type 2 diabetes
8. Genetically modified crops in India produced greater yields, reduced pesticide use, new study finds
9. Genetically modified crops may pass helpful traits to weeds, study finds
10. Genetically modified eggplants (aubergines) shown to be 30% more productive
11. Genetically modified crops -- what do scientists say?

Post Your Comments:
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
(Date:4/20/2015)... British Columbia and MENLO ... --  DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar ... developing and commercializing proven cancer therapies in new ... at the 106th Annual Meeting of the ... Meeting on the potential for its lead product ...
(Date:4/20/2015)... , April 20, 2015  Eli Lilly and ... data from several targeted cancer therapies, reflecting Lilly,s diverse ... (AACR) Annual Meeting 2015, held April 18-22 in ... Cancer Discoveries to Patients" is the theme of this ... Lilly,s commitment to broadening its portfolio of therapies that ...
(Date:4/20/2015)... --  Meditope Biosciences, Inc ., a biotechnology company developing ... presentation of data demonstrating the use of its SnAP ... data were presented in an abstract at the AACR ... Philadelphia . "We are ... many commercial applications that may be possible for our ...
(Date:4/17/2015)... Reed Technology and Information Services Inc. ... and submission to the U.S. Food and Drug Administration ... Distribution Report (LDR) service for manufacturers of biologics, including ... FDA’s new rule on electronic submission of LDRs. ... and timing of particular biologics introduced to the marketplace, ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3
Cached News: